Merck, Pfizer Double Size of Diabetes Drug Study to Catch Rivals - Bloomberg
Drug pipeline 4Q21 | Nature Biotechnology
Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pfizer's Pipeline Makes Progress as Sales Grow - WSJ
Pipeline Prospector March 2023: Silicon Valley Bank collapse hits biotech indices; Pfizer buys out Seagen | Pipeline Prospector Blog
Pfizer – Pharmagigant überzeugt mit attraktiver Pipeline! • news • onvista
Pfizer CEO eyes $90B Lilly, Novo battle in diabetes, obesity
Diabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio | Business Wire
Pfizer Talks Up Its Pipeline (NYSE:PFE) | Seeking Alpha
New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery
Pharmacy Pipeline Update - Healthgram
2023 Pipeline Report: Testing the Limits
Pfizer Stock: Is PFE Stock A Buy As It Shores Up Its Pipeline Ahead Of Expected Declines? | Investor's Business Daily
Is Pfizer's Research Pipeline Truly Undervalued? (NYSE:PFE) | Seeking Alpha
Pfizer's diabetes drug results in similar weight loss levels as Novo's Ozempic | Reuters
Type 2 Diabetes Mellitus- Pipeline Insight, 2022
Fresh from the biotech pipeline: fewer approvals, but biologics gain share | Nature Biotechnology
AstraZeneca's diabetes drug Farxiga fails in COVID-19 study | Reuters
Aktie: Eli Lilly ist der neue Star der Pharmabranche
The 20 Hottest Pipeline Drugs to Watch in 2019 | BioSpace
25 promising pipeline drugs - Drug Discovery and Development
How Pfizer's Allergan Purchase Will Boost Its Drug Pipeline - Knowledge at Wharton
Type 2 Diabetes Market to Grow Rapidly, Predicts DelveInsight | Key Companies Active in the Domain - Eli Lilly and Company, Regor, AstraZeneca, Eccogene, Pfizer, Novo Nordisk, Novartis, Amgen, MediciNova
There are many products in the production pipeline for Type 1 Diabetes, says GlobalData - Pharmaceutical Technology
